Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7985131 | 0.86 | ACE2 (0.33) | ACACB | |
| SCHEMBL5738491 | 0.86 | FFAR1 (0.44) | CYP26A1ACACB | |
| SCHEMBL6426394 | 0.78 | PTGS2 (0.35) | ACACB | |
| SCHEMBL5735231 | 0.78 | ACACB (0.41) | ACACB | |
| SCHEMBL7202310 | 0.75 | HSP90AA1 (0.32) | ACACB | |
| SCHEMBL5734793 | 0.64 | FFAR1 (0.53) | CYP26A1ACACB | |
| SCHEMBL5737348 | 0.64 | FFAR1 (0.53) | CYP26A1ACACB | |
| SCHEMBL6155431 | 0.63 | ACACB (0.42) | ACACB | |
| SCHEMBL7985128 | 0.60 | ACE2 (0.34) | — | |
| SCHEMBL5737048 | 0.60 | FFAR1 (0.43) | CYP26A1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6603019-B2 | Phenylacetic or heteroarylacetic acid derivatives, retinoic acid inducible enzyme, used to treat diseases responsive to retinoids | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020156082-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ROLR, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156082-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | CYP26A1 6/4885ACACB 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.